PARP inhibitors and prostate cancer: A new era of precision medicine

Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain

4 Aug 2020

Oncology pharmacist perspective on PARP inhibitors for castration-resistant pros...

Dr Grace Martin - The University of Kansas Cancer Center, Kansas City, USA

27 Jul 2020

The role of PARP-2 in inhibiting prostate cancer

Prof Li Jia - Harvard Medical School, Boston, USA

27 Jul 2020

Lung cancer updates from ASCO 2020

Dr Luis Raez - Memorial Cancer Institute, Florida, USA

17 Jul 2020

KEYNOTE-427 updates: First-line pembrolizumab monotherapy in patients with advan...

Prof Scott Tykodi - University of Washington, Seattle, USA

14 Jul 2020

Association of gene expression with clinical outcomes in RCC patients treated wi...

Prof Scott Tykodi - University of Washington, Seattle, USA

14 Jul 2020

Renal cell cancer: Highlights from ASCO 2020

Prof Scott Tykodi - University of Washington, Seattle, USA

13 Jul 2020

FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-re...

Prof Scott Tykodi - University of Washington, Seattle, USA

13 Jul 2020

HERO: Relugolix versus leuprolide acetate for advanced prostate cancer

Dr Neal Shore - Carolina Urologic Research Center, South Carolina, USA

10 Jul 2020

The future of PARP inhibitors in prostate cancer

Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain

2 Jul 2020

COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected st...

Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany

30 Jun 2020

IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

30 Jun 2020

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC

Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany

30 Jun 2020

ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer

Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany

24 Jun 2020

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemot...

Dr Fatima Cardoso - Champalimaud Clinical Center, Lisbon, Portugal

18 Jun 2020

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into live...

Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, US...

17 Jun 2020

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

17 Jun 2020

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA

16 Jun 2020

Pembrolizumab vs brentuximab vedotin in relapsed or refractory classic Hodgkin l...

Dr John Kuruvilla - Princess Margaret Cancer Centre, Toronto, Canada

16 Jun 2020

FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2...

Prof Robert Huddart and Dr Ignacio Durán

15 Jun 2020

Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for re...

Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA

15 Jun 2020

High-dose twice daily thoracic radiotherapy in limited disease small-cell lung c...

Prof Bjørn Henning Grønberg - Trondheim University Hospital, Trondheim, Norway

15 Jun 2020

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for ...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

15 Jun 2020

Background of the KEYLYNK-007 trial for advanced solid tumours

Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA

13 Jun 2020

CTC count as a prognostic marker for androgen deprivation plus orteronel or bica...

Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA

12 Jun 2020

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in...

Prof Thierry Conroy - Institute Cancer De Lorraine, Nancy, France

12 Jun 2020

AGO DESKTOP III/ENGOT-ov20: Impact of secondary cytoreductive surgery in recurre...

Prof Andreas du Bois - Kliniken Essen Mitte, Essen, Germany

12 Jun 2020

Three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based thera...

Prof Alberto Sobrero - Ospedale Policlinico San Martino, Genova, Italy

12 Jun 2020

Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma

Dr Katie Kelley - University of California San Francisco, San Francisco, USA

12 Jun 2020

Reducing damage to swallowing muscles during radiotherapy for head and neck canc...

Prof Christopher Nutting - The Royal Marsden NHS Foundation Trust, London, UK

12 Jun 2020

Updated results from KEYNOTE-426 for metastatic kidney cancer

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

12 Jun 2020

HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve p...

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

12 Jun 2020

Comment: JAVELIN-100 for metastatic urothelial cancer

Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA

12 Jun 2020

3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and n...

Dr Naomi Kiyota - Kobe University, Kobe, Japan

12 Jun 2020

Osimertinib plus gefitinib for treatment of EGFR-mutated non-small cell lung can...

Dr Julia Rotow - Dana Farber Cancer Institute, Boston, USA

12 Jun 2020

METex14 SAs (MET exon 14 skipping alterations) in non-small cell lung cancer

Prof Mark Awad - Dana Farber Cancer Institute, Boston, USA

12 Jun 2020

PARP inhibitors in prostate cancer: Choices of tests and how to test?

Dr Kim Chi and Dr Alexander Wyatt

11 Jun 2020

ASCO 2020: Breast cancer roundup

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

11 Jun 2020

FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple mye...

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

11 Jun 2020

The PANDA study: Combining panitumumab with FOLFOX or 5FU in elderly patients wi...

Dr Sara Lonardi - Istituto Oncologico Veneto, Padua, Italy

11 Jun 2020

Comparing pevonedistat plus azacitidine versus azacitidine alone in patients wit...

Prof Lionel Ades - Hôpital Saint-Louis, Paris, France

11 Jun 2020

ASCO 2020 prostate cancer highlights

Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl

10 Jun 2020

Perioperative novel systemic immunotherapy-based approaches in urinary cancers

Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA

9 Jun 2020

ASCO 2020: Updates in renal cancer

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

5 Jun 2020

TROPHIMMUN: Avelumab for gestational trophoblastic tumours resistant to monochem...

Prof Benoit You - Hospices Civils de Lyon, Lyon, France

5 Jun 2020

KEYNOTE-177 results: Pembrolizumab versus chemotherapy for patients with MSI-H/d...

Prof Thierry Andre - Sorbonne University and Saint-Antoine Hospital, Paris, Fran...

5 Jun 2020

Highlights from ASCO 2020

Dr Bishal Gyawali - Queen's University, Kingston, Canada

5 Jun 2020

PARP inhibitors in prostate cancer: Guidelines, who to test and the patient path...

Dr Neal Shore and Dr Elena Castro

5 Jun 2020

New emerging treatment options and targeted therapies for bladder cancer

Dr Arlene Siefker-Radtke and Dr Yohann Loriot

4 Jun 2020

Timing of response to venetoclax combination treatment in older patients with ac...

Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sac...

3 Jun 2020

CheckMate 227 three-year update: Nivolumab plus ipilimumab versus chemo as first...

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...

2 Jun 2020

ASCO 2020: Latest developments in EGFR-mutated non-small cell lung cancer

Prof Benjamin Besse and Dr Alex Spira

2 Jun 2020

Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple mye...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

1 Jun 2020

KRd vs VRd for initial therapy of newly diagnosed multiple myeloma

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

1 Jun 2020

Teclistamab for patients with heavily pretreated relapsed or refractory multiple...

Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA

1 Jun 2020

E2108: Systemic therapy plus early local therapy versus systemic therapy alone i...

Dr Seema Ahsan Khan - Northwestern Memorial Hospital, Chicago, USA

31 May 2020

KEYNOTE-604: Pembrolizumab plus etoposide and platinum as a first-line therapy f...

Dr Charles Rudin - Memorial Sloan Kettering Cancer Center, New York City, USA

31 May 2020

Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and ...

Dr Dimpy Shah - Mays Cancer Center at UT Health San Antonio MD Anderson, San Ant...

31 May 2020

Cumulative incidence of financial hardship in metastatic colorectal cancer patie...

Dr Veena Shankaran - Fred Hutchinson Cancer Research Center, Seattle, USA

30 May 2020

Denosumab in multiple myeloma patients with renal insufficiency

Dr Elizabeth O'Donnell - Massachusetts General Hospital, Boston, USA

30 May 2020

Association of BRCA alterations with response to PARP inhibitors in metastatic c...

Dr Emmanuel Antonarakis - John Hopkins Sidney Kimmel Comprehensive Cancer Center...

30 May 2020

LuPSMA vs cabazitaxel in metastatic castration-resistant prostate cancer progres...

Prof Michael Hofman - Peter MacCallum Cancer Centre, Melbourne, Australia

30 May 2020

The paediatric precision oncology study INFORM: Clinical outcome and benefit for...

Dr Cornelis van Tilburg - Hopp Children's Cancer Center Heidelberg, Heidelberg, ...

30 May 2020

Maintenance avelumab plus best supportive care (BSC) versus BSC alone after chem...

Prof Thomas Powles - Barts Cancer Institute, London, UK

29 May 2020

Brigatinib for NSCLC, latest research and overcoming complications

Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA

29 May 2020

Sym015 shows superior specificity compared to TKIs for NSCLC

Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA

29 May 2020

CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell th...

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

29 May 2020

Update from KAITLIN for high-risk HER2-positive early breast cancer

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

29 May 2020

Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate...

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

29 May 2020

Better genetic diagnostics in Ugandan breast cancer patients

Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

29 May 2020

ADAURA results: Adjuvant osimertinib for EGFRm non-small cell lung cancer

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

29 May 2020

Pembrolizumab plus chemotherapy for patients with metastatic triple-negative bre...

Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain

27 May 2020